Centauri Therapeutics secures a £6m Series A extension from AMR Action Fund to target drug-resistant bacterial infections with immunotherapy

Centauri Therapeutics is a biotechnology startup developing immunotherapies using its Alphamer platform. Its treatments are designed to harness the body’s immune response to target infectious diseases, including multidrug-resistant bacteria.